Alexander Voldman, DO
Ophthalmology · Milford, CTNPI 1659622900
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), speaking fees and education — rather than concentrated in one kind of arrangement. Alcon accounts for 69.2% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $2,462, 2.3 times the $1,061 reported in 2019. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $107.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- Sight Sciences, Inc.$433
- Glaukos Corporation$204
- Tarsus Pharmaceuticals, Inc.$197
- Carl Zeiss Meditec Cataract Technology Inc.$192
- Johnson & Johnson Surgical Vision, Inc.$191
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$3,50048%
- Food & beverage$3,76552%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $5,036 |
| Sight Sciences, Inc. | 4 | $433 |
| Glaukos Corporation | 1 | $204 |
| Tarsus Pharmaceuticals, Inc. | 4 | $197 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $192 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $191 |
| AbbVie(2 entities) | 6 | $169 |
| Shire North American Group Inc | 2 | $145 |
| Omeros Corporation | 1 | $118 |
| Dompe US, Inc. | 5 | $112 |
| Sun Pharmaceutical Industries Inc. | 1 | $86 |
| Regeneron | 1 | $86 |
| Bausch & Lomb Americas Inc. | 3 | $60 |
| Novartis | 4 | $57 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $43 |
| Harrow Eye, LLC | 2 | $37 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Rxsight Inc | 1 | $23 |
| Amgen | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Oyster Point Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$2,056
- ARGOS$1,750
- Clareon$299
- OMNI(R) SURGICAL SYSTEM (US)$296
- iDoseTR$204
- Centurion$150
- AcrySof IQ VIVITY$149
- PanOptix$148
- OMNI$128
- ACTIVEFOCUS$127
- AcrySof$127
- XIIDRA$125
- XDEMVY$124
- OMIDRIA$118
How this compares
$7,282 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 132 | $169,177 |
| Cyclosporine | 61 | $35,675 |
| LumiganBimatoprost | 15 | $8,265 |
| Prednisolone Acetate | 139 | $6,121 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $4,408 |
| Loteprednol Etabonate | 24 | $4,163 |
| Latanoprost | 339 | $2,717 |
| MoxifloxacinMoxifloxacin Hcl | 55 | $1,242 |
| ValacyclovirValacyclovir Hcl | 13 | $1,005 |
| Travoprost | 14 | $997 |
| ErythromycinErythromycin Base | 73 | $793 |
| Timolol Maleate | 86 | $539 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $359 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $350 |
| Brimonidine Tartrate | 18 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $169 | $177,442147 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $43 | $4,16324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Milford
- Brendan LawsonMilford$6K
- David LevinsonMilford$3K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.